Prostaglandin H synthase-catalyzed bioactivation of amphetamines to free radical intermediates that cause CNS regional DNA oxidation and nerve terminal degeneration

FASEB Journal

Volumn 20, Issue 6, 2006, Pages 638-650

  Jeng, Winnie ^a,c   Ramkissoon, Annmarie ^a,b   Parman, Toufan ^a,d   Wells, Peter G ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UK   (United States)

^d SRI INTERNATIONAL   (United States)

Author keywords

Brainstem; Dna oxidation; MDMA; Methamphetamine

Indexed keywords

3,4 METHYLENEDIOXYAMPHETAMINE; 8 HYDROXYDEOXYGUANOSINE; ACETYLSALICYLIC ACID; AMPHETAMINE; FREE RADICAL; METHAMPHETAMINE; PROSTAGLANDIN SYNTHASE; REACTIVE OXYGEN METABOLITE; TYROSINE 3 MONOOXYGENASE; 3,4 METHYLENEDIOXYMETHAMPHETAMINE; ADRENERGIC RECEPTOR AFFECTING AGENT; AMPHETAMINE DERIVATIVE; DNA; PROSTAGLANDIN SYNTHASE INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN REGION; CENTRAL NERVOUS SYSTEM; DNA DAMAGE; DOPAMINERGIC NERVE CELL; ENZYME ACTIVATION; FEMALE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MOTOR DYSFUNCTION; MOUSE; NERVE DEGENERATION; NONHUMAN; OXIDATION; PRIORITY JOURNAL; STEREOCHEMISTRY; SYNAPSE; ANIMAL; BRAIN; CHEMICAL STRUCTURE; CHEMISTRY; DOSE RESPONSE; DRUG EFFECT; METABOLISM; OXIDATION REDUCTION REACTION; PATHOLOGY; PSYCHOMOTOR PERFORMANCE;

3,4-METHYLENEDIOXYAMPHETAMINE; ADRENERGIC UPTAKE INHIBITORS; AMPHETAMINES; ANIMALS; ASPIRIN; BRAIN; CYCLOOXYGENASE INHIBITORS; DNA; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FREE RADICALS; METHAMPHETAMINE; MICE; MOLECULAR STRUCTURE; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; OXIDATION-REDUCTION; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PSYCHOMOTOR PERFORMANCE; SYNAPSES;

EID: 33646264063     PISSN: 08926638     EISSN: None     Source Type: Journal    
DOI: 10.1096/fj.05-5271com     Document Type: Article

References (76)

1. Kalant, H. (2001) The pharmacology and toxicology of "ecstasy" (MDMA) and related drugs. CMAJ 165, 917-928
2. Bolla, K. I., McCann, U. D., and Ricaurte, G. A. (1998) Memory impairment in abstinent MDMA ("Ecstasy") users. Neurology 51, 1532-1537
3. McGuire, P. (2000) Long term psychiatric and cognitive effects of MDMA use. Toxicol. Lett. 112-113, 153-156
4. Volkow, N. D., Chang, L., Wang, G. J., Fowler, J. S., Franceschi, D., Sedler, M., Gatley, S. J., Miller, E., Hitzemann, R., Ding, Y. S., et al. (2001) Loss of dopamine transporters in methamphetamine abusers recovers with protracted abstinence. J. Neurosci. 21, 9414-9418
5. Volkow, N. D., Chang, L., Wang, G. J., Fowler, J. S., Leonido-Yee, M., Franceschi, D., Sedler, M. J., Gatley, S. J., Hitzemann, R., Ding, Y. S., et al. (2001) Association of dopamine transporter reduction with psychomotor impairment in methamphetamine abusers. Am. J. Psychiatry 158, 377-382
6. Cadet, J. L., and Brannock, C. (1998) Free radicals and the pathobiology of brain dopamine systems. Neurochem. Int. 32, 117-131
7. Obrocki, J., Buchert, R., Vaterlein, O., Thomasius, R., Beyer, W., and Schiemann, T. (1999) Ecstasy - long-term effects on the human central nervous system revealed by positron emission tomography. Br. J. Psychiatry 175, 186-188
8. Lim, H. K., and Foltz, R. L. (1988) In vivo and in vitro metabolism of 3,4-(methylenedioxy)methamphetamine in the rat: identification of metabolites using an ion trap detector. Chem. Res. Toxicol. 1, 370-378
9. Lin, L. Y., Di Stefano, E. W., Schmitz, D. A., Hsu, L., Ellis, S. W., Lennard, M. S., Tucker, G. T., and Cho, A. K. (1997) Oxidation of methamphetamine and methylenedioxymethamphetamine by CYP2D6. Drug Metab. Dispos. 25, 1059-1064
10. Tucker, G. T., Lennard, M. S., Ellis, S. W., Woods, H. F., Cho, A. K., Lin, L. Y., Hiratsuka, A., Schmitz, D. A., and Chu, T. Y. (1994) The demethylenation of methylenedioxymethamphetamine ("ecstasy") by debrisoquine hydroxylase (CYP2D6). Biochem. Pharmacol. 47, 1151-1156
11. Warner, M., Hellmold, H., Yoshida, S., Liao, D., Hedlund, E., and Gustafsson, J. A. (1997) Cytochrome P450 in the breast and brain: role in tissue-specific activation of xenobiotics. Mutat. Res. 376, 79-85
12. Sasame, H. A., Ames, M. M., and Nelson, S. D. (1977) Cytochrome P-450 and NADPH cytochrome c reductase in rat brain: formation of catechols and reactive catechol metabolites. Biochem. Biophys. Res. Commun. 78, 919-926
13. Pelkonen, O., Maenpaa, J., Taavitsainen, P., Rautio, A., and Raunio, H. (1998) Inhibition and induction of human cytochrome P450 (CYP) enzymes. Xenobiotica 28, 1203-1253
14. Warner, M., and Gustafsson, J. A. (1994) Effect of ethanol on cytochrome P450 in the rat brain. Proc. Natl. Acad. Sci. USA 91, 1019-1023
15. Colado, M. I., Williams, J. L., and Green, A. R. (1995) The hyperthermic and neurotoxic effects of "Ecstasy" (MDMA) and 3,4 methylenedioxyamphetamine (MDA) in the Dark Agouti (DA) rat, a model of the CYP2D6 poor metabolizer phenotype. Br. J. Pharmacol. 115, 1281-1289
16. O'Neill, G. P., and Ford-Hutchinson, A. W. (1993) Expression of mRNA for cyclooxygenase-1 and cyclooxygenase-2 in human tissues. FEBS Lett. 330, 156-160
17. Morita, I., Schindler, M., Regier, M. K., Otto, J. C., Hori, T., DeWitt, D. L., and Smith, W. L. (1995) Different intracellular locations for prostaglandin endoperoxide H synthase-1 and -2. J. Biol. Chem. 270, 10902-10908
18. Smith, W. L., Garavito, R. M., and DeWitt, D. L. (1996) Prostaglandin endoperoxide H synthases (cyclooxygenases)-1 and -2. J. Biol. Chem. 271, 33157-33160
19. Vane, J. R., Bakhle, Y. S., and Botting, R. M. (1998) Cyclooxygenases 1 and 2. Annu. Rev. Pharmacol. Toxicol. 38, 97-120
20. Wells, P. G., and Winn, L. M. (1996) Biochemical toxicology of chemical teratogenesis. Crit. Rev. Biochem. Mol. Biol. 31, 1-40
21. Wells, P. G., Kim, P. M., Laposa, R. R., Nicol, C. J., Parman, T., and Winn, L. M. (1997) Oxidative damage in chemical teratogenesis. Mutat. Res. 396, 65-78
22. Wells, P. G., Kim, P., Nicol, C., Parman, T., and Winn, L. (1997) Reactive Intermediates. In Drug Toxicity in Embryonic Development (Kavlock, R., and Daston, D., eds) Vol. 124, Part I, pp. 453-518, Springer-Verlag, Heidelberg
23. Winn, L. M., and Wells, P. G. (1997) Evidence for embryonic prostaglandin H synthase-catalyzed bioactivation and reactive oxygen species-mediated oxidation of cellular macromolecules in phenytoin and benzo[a]pyrene teratogenesis. Free Radic. Biol. Med. 22, 607-621
24. Winn, L. M., and Wells, P. G. (1999) Maternal administration of superoxide dismutase and catalase in phenytoin teratogenicity. Free Radic. Biol. Med. 26, 266-274
25. Parman, T., Chen, G., and Wells, P. G. (1998) Free radical intermediates of phenytoin and related teratogens. Prostaglandin H synthase-catalyzed bioactivation, electron paramagnetic resonance spectrometry, and photochemical product analysis. J. Biol. Chem. 273, 25079-25088
26. Parman, T., and Wells, P. G. (2002) Embryonic prostaglandin H synthase-2 (PHS-2) expression and benzo[a]pyrene teratogenicity in PHS-2 knockout mice. FASEB J. 16, 1001-1009
27. Nicol, C. J., Zielenski, J., Tsui, L. C., and Wells, P. G. (2000) An embryoprotective role for glucose-6-phosphate dehydrogenase in developmental oxidative stress and chemical teratogenesis. FASEB J. 14, 111-127
28. Liu, L., and Wells, P. G. (1995) DNA oxidation as a potential molecular mechanism mediating drug-induced birth defects: phenytoin and structurally related teratogens initiate the formation of 8-hydroxy-2′-deoxyguanosine in vitro and in vivo in murine maternal hepatic and embryonic tissues. Free Radic. Biol. Med. 19, 639-648
29. Roberts, L. J., II, and Morrow, J. D. (2001) Analgesic-antipyretic and antiinflammatory agents and drugs employed in the treatment of gout. In The Pharmacological Basis of Therapeutics (Hardman, J. G., and Limbird, L. E., eds) pp. 687-703, McGraw-Hill, New York
30. Teismann, P., and Ferger, B. (2001) Inhibition of the cyclooxygenase isoenzymes COX-1 and COX-2 provide neuroprotection in the MPTP-mouse model of Parkinson's disease. Synapse 39, 167-174
31. Markwell, M. A., Haas, S. M., Tolbert, N. E., and Bieber, L. L. (1981) Protein determination in membrane and lipoprotein samples: manual and automated procedures. In Methods in Enzymology (Colonick, S. P., and Kapla, N. O., eds) Vol. 72, pp. 296-303, Academic Press, New York
32. Johnson, M., Letter, A. A., Merchant, K., Hanson, G. R., and Gibb, J. W. (1988) Effects of 3,4-methylenedioxyamphetamine and 3,4- methylenedioxymethamphetamine isomers on central serotonergic, dopaminergic and nigral neurotensin systems of the rat. J. Pharmacol. Exp. Ther. 244, 977-982
33. 3H]dopamine release from superfused rat brain slices. Eur. J. Pharmacol. 132, 269-276
34. Marquardt, G. M., DiStefano, V., and Ling, L. L. (1978) Pharmacological and toxicological effects of beta-3,4-methylenedioxyamphetamine isomers. Toxicol. Appl. Pharmacol. 45, 675-683
35. Marquardt, G. M., DiStefano, V., and Ling, L. L. (1978) Pharmacological effects of (+/-)-, (S)-, and (R)-MDA. In The Psychopharmacology of Hallucinogens (Stillman, R. C., and Willette, R. E., eds) pp. 84-104, Pergamon Press, New York
36. Schmidt, C. J. (1987) Acute administration of methylenedioxymethamphetamine: comparison with the neurochemical effects of its N-desmethyl and N-ethyl analogs. Eur. J. Pharmacol. 136, 81-88
37. Eling, T. E., Thompson, D. C., Foureman, G. L., Curtis, J. F., and Hughes, M. F. (1990) Prostaglandin H synthase and xenobiotic oxidation. Annu. Rev. Pharmacol. Toxicol. 30, 1-45
38. Marnett, L. J., and Eling, T. E. (1983) Cooxidation during prostaglandin biosynthesis: a pathway for the metabolic activation of xenobiotics. In Reviews in Biochemical Toxicology (Hodgson, E., Bend, J. R., and Philpott, R. M., eds) pp. 135-172, Elsevier, New York
39. O'Callaghan, J. P., and Miller, D. B. (1994) Neurotoxicity profiles of substituted amphetamines in the C57BL/6J mouse. J. Pharmacol. Exp. Ther. 270, 741-751
40. Bernheimer, H., Birkmayer, W., Hornykiewicz, O., Jellinger, K., and Seitelberger, F. (1973) Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. J. Neurol. Sci. 20, 415-455
41. Jeng, W., and Wells, P. G. (2003) Reduced stereoselective 3,4-methylenedioxymethamphetamine (ecstasy)-initiated oxidative DNA damage and neurodegeneration in prostaglandin H synthase-1 knockout mice. Toxicol. Sci. 72(S-1), 72
42. Wells, P. G., Bhuller, Y., Chen, C. S., Jeng, W., Kasapinovic, S., Kennedy, J. C., Kim, P. M., Laposa, R. R., McCallum, G. P., Nicol, C. J., et al. (2005) Molecular and biochemical mechanisms in teratogenesis involving reactive oxygen species. Toxicol. Appl. Pharmacol. 207(2S), 354-366
43. Marnett, L. J. (1995) Aspirin and related nonsteroidal antiinflammatory drugs as chemopreventive agents against colon cancer. Prev. Med. 24, 103-106
44. Launer, L. (2003) Nonsteroidal anti-inflammatory drug use and the risk for Alzheimer's disease: dissecting the epidemiological evidence. Drugs 63, 731-739
45. Marnett, L. J., and DuBois, R. N. (2002) COX-2: a target for colon cancer prevention. Annu. Rev. Pharmacol. Toxicol. 42, 55-80
46. Halliwell, B., and Gutteridge, J. M. C. (1999) Free Radicals in Biology and Medicine, 3rd Ed, Clarendon Press, Oxford
47. Breder, C. D., Dewitt, D., and Kraig, R. P. (1995) Characterization of inducible cyclooxygenase in rat brain. J. Comp. Neurol. 355, 296-315
48. Kaufmann, W. E., Andreasson, K. I., Isakson, P. C., and Worley, P. F. (1997) Cyclooxygenases and the central nervous system. Prostaglandins 54, 601-624
49. Spencer, A. G., Woods, J. W., Arakawa, T., Singer, I. I., and Smith, W. L. (1998) Subcellular localization of prostaglandin endoperoxide H synthases-1 and -2 by immunoelectron microscopy. J. Biol. Chem. 273, 9886-9893
50. Frederick, D. L., and Paule, M. G. (1997) Effects of MDMA on complex brain function in laboratory animals. Neurosci. Biobehav. Rev. 21, 67-78
51. Ricaurte, G. A., Yuan, J., and McCann, U. D. (2000) (+/-)3,4- Methylenedioxymethamphetamine ('Ecstasy')-induced serotonin neurotoxicity: studies in animals. Neuropsychobiology 42, 5-10
52. Thomas, D. M., and Kuhn, D. M. (2005) Cyclooxygenase-2 is an obligatory factor in methamphetamine-induced neurotoxicity. J. Pharmacol. Exp. Ther. 313, 870-876
53. Jeng, W., and Wells, P. G. (2004) Free radical determinants of amphetamine neurodegeneration: prostaglandin H synthase (PHS)-catalyzed free radical formation and reactive oxygen species (ROS)-mediated oxidative DNA damage in neuronal degeneration and functional deficits. Toxicol. Sci. 78(S-1), 413
54. Kita, T., Shimada, K., Mastunari, Y., Wagner, G. C., Kubo, K., and Nakashima, T. (2000) Methamphetamine-induced striatal dopamine neurotoxicity and cyclooxygenase-2 protein expression in BALB/c mice. Neuropharmacology 39, 399-406
55. Dash, P. K., Mach, S. A., and Moore, A. N. (2000) Regional expression and role of cyclooxygenase-2 following experimental traumatic brain injury. J. Neurotrauma 17, 69-81
56. Valyi-Nagy, T., Sidell, K. R., Marnett, L. J., Roberts, L. J., II, Dermody, T. S., Morrow, J. D., and Montine, T. J. (1999) Divergence of brain prostaglandin H synthase activity and oxidative damage in mice with encephalitis. J. Neuropathol. Exp. Neurol. 58, 1269-1275
57. Oka, A., and Takashima, S. (1997) Induction of cyclo-oxygenase 2 in brains of patients with Down's syndrome and dementia of Alzheimer type: specific localization in affected neurones and axons. NeuroReport 8, 1161-1164
58. Walsh, D. T., Perry, V. H., and Minghetti, L. (2000) Cyclooxygenase-2 is highly expressed in microglial-like cells in a murine model of prion disease. Glia 29, 392-396
59. Feng, Z. H., Wang, T. G., Li, D. D., Fung, P., Wilson, B. C., Liu, B., Ali, S. F., Langenbach, R., and Hong, J. S. (2002) Cyclooxygenase-2-deficient mice are resistant to 1-methyl-4-phenyl1, 2, 3, 6-tetrahydropyridine-induced damage of dopaminergic neurons in the substantia nigra. Neurosci. Lett. 329, 354-358
60. Pompl, P. N., Ho, L., Bianchi, M., McManus, T., Qin, W., and Pasinetti, G. M. (2003) A therapeutic role for cyclooxygenase-2 inhibitors in a transgenic mouse model of amyotrophic lateral sclerosis. FASEB J. 17, 725-727
61. Sprague, J. E., and Nichols, D. E. (1995) The monoamine oxidase-B inhibitor L-deprenyl protects against 3,4-methylenedioxymethamphetamine-induced lipid peroxidation and long-term serotonergic deficits. J. Pharmacol. Exp. Ther. 273, 667-673
62. Gluck, M. R., Moy, L. Y., Jayatilleke, E., Hogan, K. A., Manzino, L., and Sonsalla, P. K. (2001) Parallel increases in lipid and protein oxidative markers in several mouse brain regions after methamphetamine treatment. J. Neurochem. 79, 152-160
63. Beckman, K. B., and Ames, B. N. (1998) The free radical theory of aging matures. Physiol. Rev. 78, 547-581
64. Coyle, J. T., and Puttfarcken, P. (1993) Oxidative stress, glutamate, and neurodegenerative disorders. Science 262, 689-695
65. Mecocci, P., MacGarvey, U., Kaufman, A. E., Koontz, D., Shoffner, J. M., Wallace, D. C., and Beal, M. F. (1993) Oxidative damage to mitochondrial DNA shows marked age-dependent increases in human brain. Ann. Neurol. 34, 609-616
66. Mecocci, P., Cherubini, A., Beal, M. F., Cecchetti, R., Chionne, F., Polidori, M. C., Romano, G., and Senin, U. (1996) Altered mitochondrial membrane fluidity in AD brain. Neurosci. Lett. 207, 129-132
67. Mecocci, P., MacGarvey, U., and Beal, M. F. (1994) Oxidative damage to mitochondrial DNA is increased in Alzheimer's disease. Ann. Neurol. 36, 747-751
68. Freeman, B. A., and Crapo, J. D. (1982) Biology of disease: free radicals and tissue injury. Lab. Invest. 47, 412-426
69. Allen, R. G., and Tresini, M. (2000) Oxidative stress and gene regulation. Free Radic. Biol. Med. 28, 463-499
70. White, S. R., Obradovic, T., Imel, K. M., and Wheaton, M. J. (1996) The effects of methylenedioxymethamphetamine (MDMA, "Ecstasy") on monoaminergic neurotransmission in the central nervous system. Prog. Neurobiol. 49, 455-479
71. Nicol, C. J., Harrison, M. L., Laposa, R. R., Gimelshtein, I. L., and Wells, P. G. (1995) A teratologic suppressor role for p53 in benzo[a]pyrene-treated transgenic p53-deficient mice. Nat. Genet. 10, 181-187 (published erratum appears in Nat. Genet. 1995,11:104)
72. Laposa, R. R., Henderson, J. T., Xu, E., and Wells, P. G. (2004) Atm-null mice exhibit enhanced radiation-induced birth defects and a hybrid form of embryonic programmed cell death indicating a teratological suppressor function for ATM. FASEB J. 18, 896-898
73. Wong, A. W., Jeng, W., and Wells, P. G. (2004) Methamphetamine-initiated neurodevelopmental deficits are enhanced in oxoguanine glycosylase 1 (OGG1) knockout mice. Toxicol. Sci., 78(S-1), 380
74. Mintzer, S., Hickenbottom, S., and Gilman, S. (1999) Parkinsonism after taking ecstasy. N. Engl. J. Med. 340, 1443
75. Guilarte, T. R. (2001) Is methamphetamine abuse a risk factor in parkinsonism? Neurotoxicology 22, 725-731
76. Parrott, A. C., Buchanan, T., Scholey, A. B., Heffernan, T., Ling, J., and Rodgers, J. (2002) Ecstasy/MDMA attributed problems reported by novice, moderate and heavy recreational users. Hum. Psychopharmacol. 17, 309-312